NCT04603404 Multimodality Imaging in the Screening, Diagnosis and Risk StratifictiON of HFpEF
| NCT ID | NCT04603404 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital |
| Condition | Heart Failure, Diastolic |
| Study Type | OBSERVATIONAL |
| Enrollment | 430 participants |
| Start Date | 2019-01-01 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 430 participants in total. It began in 2019-01-01 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The incidence of Heart failure with preserved ejection fraction (HFpEF) in Heart failure patients increases rapidly. However, the current clinical awareness is insufficient, and the cardiac structural and functional injury are not well understood. It is difficult to recognize the subclinical changes of the cardiac in the early stage with conventional imaging techniques, and it is common to ignore the existence of the clinical alterations. This study aimed to investigate the cardiac features, early diagnosis and risk factors of HFpEF patients, based on the multi-modal (Magnetic resonance imaging- nuclear medicine imaging- echocardiography) imaging, combined with large data and artificial intelligence. This study will provide deep insights into the HFpEF derived from different causes.
Eligibility Criteria
Inclusion Criteria: * left ventricular ejection fraction (LVEF)≥50%； * N-terminal pro-b type natriuretic peptide (NT-proBNP)\>220pg/ml or b type natriuretic peptide (BNP) \>80 pg/ml; * symptoms and syndromes of heart failure; * At least one criteria of cardiac structure (left ventricular hypertrophy, or left atrial enlargement) and function abnormalities (based on tissue doppler, color doppler). Exclusion Criteria: * Special types of cardiomyopathy, including hypertrophic cardiomyopathy, restricted cardiomyopathy, etc. * Infarction, myocardial fibrosis caused by ischemic cardiomyopathy and acute coronary syndrome ; * Severe arrhythmia; * Severe primary cardiac valvular disease; * Restrictive pericardial disease; * Refuse to participate in the study.
Contact & Investigator
Minjie Lu, PhD
PRINCIPAL INVESTIGATOR
Fuwai Hospital, National Center for Cardiovascular Diseases.
Frequently Asked Questions
Who can join the NCT04603404 clinical trial?
This trial is open to participants of all sexes, studying Heart Failure, Diastolic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04603404 currently recruiting?
Yes, NCT04603404 is actively recruiting participants. Contact the research team at coolkan@163.com for enrollment information.
Where is the NCT04603404 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT04603404 clinical trial?
NCT04603404 is sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital. The principal investigator is Minjie Lu, PhD at Fuwai Hospital, National Center for Cardiovascular Diseases.. The trial plans to enroll 430 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.